Table 6.
AEs evaluation during all phases
| Group | Total, n (%) | P valuea | ||||
|---|---|---|---|---|---|---|
| EA + CBZ (n = 30) | SEA + CBZ (n = 29) | EA + P (n = 29) | SEA + P (n = 29) | |||
| EA-related AEs, n (%) | 3 (10) | NA | 3 (10.3) | NA | ||
| Hematoma | 3 (10.0) | NA | 2 (6.9) | NA | ||
| Tingling sensation | 0 (0.0) | NA | 1 (3.4) | NA | ||
| CBZ-related AEs, n (%) | 7 (23.3) | 8 (27.6) | NA | NA | ||
| Dermatitis /itchiness | 4 (13.3) | 1 (3.4) | NA | NA | ||
| Dizziness /sleepiness | 2 (6.7) | 4 (13.8) | NA | NA | ||
| Palpitations | 1 (3.3) | 3 (10.3) | NA | NA | ||
| Total incidence of EA-related AEs, n (%) | 6 (10.2) | 0.030* | ||||
| Total incidence of CBZ-related AEs, n (%) | 15 (25.4) | |||||
aData were examined using Chi-square or Fisher Exact test
*P < 0.05
Abbreviations: NA not applicable, EA + CBZ electroacupuncture plus carbarmazepine (at the dosage of 300 mg/day), SEA + CBZ sham electroacupuncture plus carbarmazepine (at the dosage of 300 mg/day), EA + P electroacupuncture plus placebo, SEA + P sham electroacupuncture plus placebo